<DOC>
	<DOCNO>NCT00997399</DOCNO>
	<brief_summary>Panobinostat ( LBH589 ) deacetylase inhibitor ( DACi ) belong structurally novel cinnamic hydroxamic acid class compound . It one potent class I/II pan-DAC inhibitor ( pan-DACi ) show anti-tumor activity pre-clinical model patient solid tumor hematological malignancy . To date , pharmacokinetics ( PK ) panobinostat characterized patient solid tumor hematological malignancy participate several phase I/II clinical study . Panobinostat PK appear different patient solid tumor hematological malignancy . However , effect organ dysfunction PK panobinostat yet elucidate . Kidney liver involve elimination metabolism panobinostat . The current study design evaluate impact renal function status panobinostat PK .</brief_summary>
	<brief_title>Study Evaluate Panobinostat ( DACi ) Pharmacokinetics Safety Solid Tumors Varying Renal Function</brief_title>
	<detailed_description />
	<mesh_term>Panobinostat</mesh_term>
	<criteria>1 . Patient document diagnosis advance solid tumor standard systemic therapy exist 2 . Patient normal abnormal renal organ function 3 . Patient provide write informed consent prior screen procedure 1 . Patient need valproic acid medical condition study within 5 day prior first panobinostat dose 2 . Patient receive prior treatment DAC inhibitor include panobinostat 3 . Patient require dialysis 4 . Patient require diuretic unless patient take potassium spar diuretic 5 . Patient acute renal failure , history transplant , ESRD ( however acceptable severe renal impaired group ) 6 . Female patient pregnant breast feed childbearing potential willing use double method contraception 3 month end study treatment . Male patient willing use barrier method contraception 3 month end study treatment . Other protocoldefined inclusion/exclusion criterion may apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2014</verification_date>
	<keyword>Ph I</keyword>
	<keyword>panobinostat ( DACi )</keyword>
	<keyword>PK &amp; safety</keyword>
	<keyword>solid tumor</keyword>
	<keyword>vary renal function</keyword>
	<keyword>advanced</keyword>
</DOC>